|
End-of-day quote
Amman S.E.
14/09/2026
|
5-day change | 1st Jan Change | ||
| 2.000 JOD | +6.95% |
|
+5.26% | +25.00% |
| 07-22 | Philadelphia Pharmaceuticals Company Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
| 04-27 | Philadelphia Pharmaceuticals Q1 profit 255,632 dinars | RE |
| Market Cap | 15M 21.16M 18.33M 17.33M 15.73M 29.49M 2.03B 29.66M 207M 79.94M 1.03B 79.47M 77.71M 3.28B | P/E 2024 |
13.7x | P/E 2025 | 11.9x |
|---|---|---|---|---|---|
| Enterprise Value | 14.93M 21.06M 18.25M 17.25M 15.66M 29.35M 2.02B 29.53M 206M 79.58M 1.02B 79.12M 77.36M 3.27B | EV / Sales 2024 |
1.32x | EV / Sales 2025 | 1.3x |
| Free-Float |
7.27% | Yield 2024 |
4.67% | Yield 2025 | - |
| 1 day | +6.95% | ||
| 1 week | +5.26% | ||
| Current month | +5.26% | ||
| 1 month | +1.01% | ||
| 3 months | +19.05% | ||
| 6 months | +25.79% | ||
| Current year | +25.00% |
| 1 week | 2 | 2 | |
| 1 month | 1.84 | 2 | |
| Current year | 1.5 | 2.01 | |
| 1 year | 1.48 | 2.01 | |
| 3 years | 1.36 | 2.01 | |
| 5 years | 1.28 | 2.01 | |
| 10 years | 1.28 | 3.19 |
| Manager | Title | Age | Since |
|---|---|---|---|
Ashraf Hussein
CEO | Chief Executive Officer | 44 | 01/01/2013 |
Rima Shanoudeh
CTO | Chief Tech/Sci/R&D Officer | - | - |
Belal Salameh
DFI | Director of Finance/CFO | 50 | 01/01/2002 |
| Director | Title | Age | Since |
|---|---|---|---|
Munther Hussein
CHM | Chairman | 58 | - |
| Director/Board Member | 61 | 01/09/2016 | |
| Director/Board Member | 64 | 01/01/2013 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +6.95% | +5.26% | +30.72% | +39.86% | 21.16M | ||
| +1.01% | -0.61% | +15.09% | +61.20% | 45.9B | ||
| +3.03% | -1.96% | +38.13% | +101.80% | 38.7B | ||
| +0.77% | -1.77% | +7.06% | +71.61% | 11.43B | ||
| +0.52% | -0.37% | -12.89% | +9.92% | 11.38B | ||
| +0.96% | +0.57% | +19.32% | +148.82% | 9.09B | ||
| -0.47% | +0.16% | +27.34% | +36.96% | 7.3B | ||
| +1.61% | -1.03% | +16.03% | +181.38% | 6.98B | ||
| +1.70% | +1.13% | +38.60% | -19.02% | 7.13B | ||
| +0.61% | -5.43% | -43.52% | +5.23% | 4.89B | ||
| Average | +1.67% | -0.86% | +13.59% | +63.77% | 14.28B | |
| Weighted average by Cap. | +1.48% | -2.55% | +18.57% | +73.23% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 8.76M 12.36M 10.71M 10.12M 9.19M 17.22M 1.19B 17.33M 121M 46.7M 601M 46.43M 45.4M 1.92B | 9.17M 12.93M 11.21M 10.59M 9.62M 18.02M 1.24B 18.13M 126M 48.86M 629M 48.58M 47.5M 2.01B |
| Net income | 822K 1.16M 1M 949K 862K 1.61M 111M 1.62M 11.33M 4.38M 56.38M 4.35M 4.26M 180M | 1.01M 1.42M 1.23M 1.16M 1.05M 1.98M 136M 1.99M 13.86M 5.36M 68.98M 5.33M 5.21M 220M |
| Net Debt | 334K 471K 408K 385K 350K 656K 45.14M 660K 4.6M 1.78M 22.9M 1.77M 1.73M 72.98M | -67.69K -95.47K -82.73K -78.19K -70.99K -133K -9.16M -134K -933K -361K -4.65M -359K -351K -14.81M |
Employees
129
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 14/09/26 | JOD 2.000 | +6.95% | 10 |
- Stock Market
- Stocks
- PHIL Stock
Select your edition
All financial news and data tailored to specific country editions
















